ROIV Key Statistics, Chart & Performance
The current stock price of ROIV is 21.7 USD. In the past month the price increased by 7.96%. In the past year, price increased by 85.63%.
ROIV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ROIV
Company Profile
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Company Info
ROIVANT SCIENCES LTD
7Th Floor, 50 Broadway
London GB
Employees: 750
Phone: 4412955950
ROIVANT SCIENCES LTD / ROIV FAQ
What does ROIVANT SCIENCES LTD do?
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
What is the current price of ROIV stock?
The current stock price of ROIV is 21.7 USD. The price increased by 0.32% in the last trading session.
Does ROIVANT SCIENCES LTD pay dividends?
ROIV does not pay a dividend.
What is the ChartMill technical and fundamental rating of ROIV stock?
ROIV has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the expected growth for ROIV stock?
The Revenue of ROIVANT SCIENCES LTD (ROIV) is expected to decline by -80.14% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for ROIVANT SCIENCES LTD?
ROIVANT SCIENCES LTD (ROIV) has a market capitalization of 15.09B USD. This makes ROIV a Large Cap stock.
Who owns ROIVANT SCIENCES LTD?
You can find the ownership structure of ROIVANT SCIENCES LTD (ROIV) on the Ownership tab.
ROIV Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ROIV. When comparing the yearly performance of all stocks, ROIV is one of the better performing stocks in the market, outperforming 95.17% of all stocks.
ROIV Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ROIV. No worries on liquidiy or solvency for ROIV as it has an excellent financial health rating, but there are worries on the profitability.
ROIV Financial Highlights
Over the last trailing twelve months ROIV reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 17.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.39% | ||
| ROE | -8.57% | ||
| Debt/Equity | 0 |
ROIV Forecast & Estimates
18 analysts have analysed ROIV and the average price target is 26.43 USD. This implies a price increase of 21.78% is expected in the next year compared to the current price of 21.7.
For the next year, analysts expect an EPS growth of -413.26% and a revenue growth -80.14% for ROIV